Extrahepatic bile duct rhabdomyosarcoma

Summary

Extrahepatic bile duct rhabdomyosarcoma (MONDO:0002577) is a disease. A subtype of liver rhabdomyosarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	extrahepatic bile duct rhabdomyosarcoma
Mondo ID	MONDO:0002577
DOID	DOID:3254
NCIT	C5860
UMLS	C2064434
MedGen	473530
GARD	0023172
Anatomy (UBERON)	UBERON:0003703
Is cancer (heuristic)	no

Also known as: bile duct rhabdomyosarcoma (disease) · extrahepatic bile duct rhabdomyosarcoma · extrahepatic bile duct rhabdomyosarcoma (disease) · rhabdomyosarcoma (disease) of extrahepatic bile duct · rhabdomyosarcoma of extrahepatic bile duct · rhabdomyosarcoma of the extrahepatic bile duct

Disease family

This is a subtype of liver rhabdomyosarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › liver cancer › liver sarcoma › liver rhabdomyosarcoma › extrahepatic bile duct rhabdomyosarcoma

Subtypes (1): embryonal extrahepatic bile duct rhabdomyosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.